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proliferation, apoptosis, metastasis, genomic stability, metabolism and therapy resistance. 4, 5 LncRNAs can also function as ceRNAs, binding to miRNAs and protecting their target RNAs from repression or degradation. 6 Several studies have identified an involvement for lncRNAs in breast cancer. [7] [8] [9] [10] HOX antisense intergenic RNA (HOTAIR) 11 affects the expression of numerous downstream genes by interacting with polycomb repressive complex 2 (PRC2), which can further promote H3K27 methylation. 12 Chandra Gupta et al 13 showed that HOTAIR acts as a powerful predictor for breast cancer and functions in breast cancer development. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), first identified in nonsmall cell lung cancer, is also involved in the proliferation, invasion and migration of breast cancer cells. [14] [15] [16] The lncRNA OIP5-AS1, known as cyrano in zebrafish, is a 1.894-kb transcript that lacks protein-coding ability. OIP5-AS1 is overexpressed in the nervous system and is important for controlling neurogenesis during development. 17 Several studies have indicated that OIP5-AS1 may play different roles in various tumors. OIP5-AS1 reduced the proliferation of HeLa cervical carcinoma cells by acting as a ceRNA for
HuR. 18 OIP5-AS1 also regulates mitosis in HeLa cells by inhibiting GAK expression. 19 Hu et al 20 showed that OIP5-AS1 was overexpressed in glioma tissues and acted as an oncogene by downregulation of YAP and inhibition of Notch signaling pathway activity. OIP5-AS1 also promoted the progression of hepatoblastoma cells and lung adenocarcinoma. 21, 22 Together, these studies indicate a function for OIP5-AS1 in cancer. However, its role in breast cancer has not been reported.
In the present study, we examined the expression of OIP5-AS1 in breast cancer tissues and human breast cancer cells and investigated its potential function in regulating breast cancer activity and progression. Our results showed that OIP5-AS1 may function as ceRNA of miR-129-5p to regulate the expression of SOX2 in breast cancer and thus plays a role in breast cancer progression. 
| MATERIAL S AND ME THODS

| Tissue samples
Seventy
| Cell culture
Human breast cancer cell lines MCF-7, MDA-MB-231, T47D, SK-BR-3 and BT-549 were obtained from the Type Culture Collection of the Chinese Academy of Sciences, Shanghai, China, and the normal human mammary epithelial cell line MCF-10A was purchased from KeyGEN Biotech Company (Nanjing, China). Cell culture conditions are listed in Table 1 . Medium was replaced every 2 days, and cells were passaged when they reached 90% confluence.
| RNA extraction and qRT-PCR assay
Total RNA was extracted from tissues and cells using TRIzol Primer sequences used for qPCR are listed in Table 2 .
| Transfection of lentivirus and plasmid vectors
The lentivirus for OIP5-AS1 inhibition (sh-OIP5-AS1), miR-129-5p
lentivirus (miR-129-5p) and negative control (NC) lentivirus were purchased from WuYuan Company (Beijing, China). Three different sequences used for sh-OIP5-AS1 and the NC sequence are as follows:
sh-a: 5′-GCUCCUAGGAUUCCAGUUAUC-3′
sh-b: 5′-GCAGAAGGCUGAGUUUCAUUU-3′
sh-c: 5′-GGUGCUUAGGUGGUGGUAUUU-3′
sh-NC: 5′-UUCUCCGAACGUGUCACGU-3′ The miR-129-5p sequence in the overexpression lentivirus was CUUUUUGCGGUCUGGGCUUGC. The negative control sequence for miR-129-5p (Coi) was UUCUCCGAACGUGUCACGU.
The SOX2 overexpression plasmid (pFUW-TETO/SOX2) and the negative control vector (pFUW-TETO/NC) were purchased from Polyamines (Yeasen, Shanghai, China) were used for lentivirus transfection and Lipo2000 (Invitrogen) was used for plasmid and miR-129-5p
inhibitor transfection according to the manufacturers' instructions.
| CCK-8 assay
Cells were seeded in 96-well plates at 5 × 10 3 cells per well in 100 μL. CCK-8 solution (10 μL) (Dojindo, Kumamoto, Japan) was added at various times and cells were incubated for 1-3 hours at 37°C. Absorbance at 450 nm (OD 450 nm) was detected using a microplate reader. 
| Colony formation assay
| Transwell assay
Membrane invasion culture system with Transwell membranes of 6.5 mm diameter and 8 μm pore size (Corning, Corning, NY, USA) was used according to standard protocol. Cells were seeded into the upper compartment at 2 × 10 4 cells per well in 200 μL DMEM without FBS.
The lower chamber was filled with 800 μL DMEM containing 20% FBS.
After 48 hours, cells on the lower surface were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. The results were counted using an inverted microscope (Olympus, Lake Success, NY, USA).
| Wound healing assay
Cells were seeded in a 6-well plate at 5 × 10 5 cells per well in 2 mL medium. After cell attachment, a 200 μL pipette tip was used to create a scratch in the cell layer. PBS was used to wash away the cells that had been scraped off, and cells were incubated for 48 hours. Wound widths were photographed and measured under a microscope at 0 and 48 hours.
| Flow cytometry
Cells were trypsinized, collected and resuspended in binding buffer Boster) and anti-caspase 3 (1:300; BM4585; Boster).
| Western blot
| Luciferase reporter assay
We constructed SOX2-wild-type (wt-SOX2), SOX2-mutant (mut-SOX2), OIP5-AS1-wild-type (wt-OIP5-AS1) and OIP5-AS1-mutant 
| Xenograft tumorigenicity assay
Ten BALB/c nude mice ( 
| Immunohistochemistry
Expressions of Ki-67 and SOX2 were evaluated using immunohistochemistry assay as previously described. 23 Briefly, slides were washed with specific reagents in the following order: xylene, two 
| TUNEL assay
Apoptosis in s.c. transplanted tumor tissues was evaluated using the TUNEL assay kit (KeyGEN) according to the manufacturer's guidelines.
| Statistical analysis
GraphPad Prism 5 (La Jolla, CA, USA) and SPSS 22.0 (Chicago, IL, USA) were used for data analysis, and the data are expressed as mean value ± (SD. Significance of OIP5-AS1 expression in breast cancer as correlated with clinicopathological characteristics was investigated using the chi-squared test. Two-tailed Student's t test was used to determine the statistical significance between the mean values of the experimental and control groups. A value of P < .05 was considered significant. 
| RE SULTS
| Opa interacting protein 5-antisense RNA 1 is significantly upregulated in breast cancer tissues and cell lines
We examined the expression of OIP5-AS1 in 70 pairs of breast cancer tissues and paired adjacent normal tissues using qRT-PCR assay. OIP5-AS1 was significantly upregulated in 70 breast cancer tissue samples compared with the paired adjacent normal tissues (P < .05) ( Figure 1A ,B). We divided the 70 patients into high and low OIP5-AS1 expression groups according to a cut-off value of twice the level observed in normal tissue and analyzed the relationship between OIP5-AS1 expression and clinical characteristics (Table 3) .
We found a correlation between high OIP5-AS1 expression and tumor size (P = .033), lymph node metastasis (P = .032), pathological grading (P = .016) and TNM stage (P = .042).
We also examined OIP5-AS1 expression in breast cancer lines, including MCF-7, T47D, BT549, SK-BR-3 and MDA-MB-231, compared with MCF-10A normal human mammary epithelial cells. OIP5-AS1
was upregulated in all five breast cancer cell lines, with SK-BR-3 and MDA-MB-231 showing the highest expression (P < .01; Figure 1C ).
We thus selected these lines for subsequent analyses.
| Downregulation of OIP5-AS1 suppresses breast cancer cell growth, proliferation and migration, and induces apoptosis in vitro
To Figure 2B ). Colony formation ability was also significantly reduced in both cell lines after downregulation of OIP5-AS1 compared with sh-NC cells (P < .01) ( Figure 2C ). Wound healing and Transwell assays showed that cell migration and invasion, respectively, were significantly inhibited in the sh-OIP5-AS1 group compared with controls (P < .01; Figure 2D ,E). Flow cytometry showed a higher apoptosis rate in sh-OIP5-AS1 cells compared with sh-NC cells (P < .01) ( Figure 2F ).
Consistent with these results, upon downregulation of OIP5-AS1, the pro-apoptotic proteins Bax and cleaved caspase 3 were increased and the anti-apoptotic protein Bcl-2 was decreased ( Figure 2G ).
| MicroRNA-129-5p binds to OIP5-AS1
To determine the mechanism of OIP5-AS1, we attempted to identify downstream molecules of OIP5-AS1. By searching the online software starBase v2.0, we found that OIP5-AS1 contains binding sites for miR-129-5p.
To determine the relationship between OIP5-AS1 and miR-129-5p, we examined miR-129-5p expression in 57 of the 70 original breast cancer cases and found low miR-129-5p expression in the breast cancer cases compared with paired adjacent tissues ( Figure 3A,B) . Furthermore, miR-129-5p and OIP5-AS1 expression were negatively correlated in breast cancer tissues ( Figure 3C ). To examine the potential binding and regulation of miR-129-5p
to OIP5-AS1, we designed a luciferase reporter containing the wildtype OIP5-AS1 3′-untranslated region (UTR) or a mutant with a mutated miR-129-5p binding site ( Figure 3D ). miR-129-5p expression decreased luciferase activity of the wt-OIP5-AS1 3′-UTR vector but not the mut-OIP5-AS1 3′-UTR vector (P < .01) ( Figure 3E ).
We next evaluated miR-129-5p expression in MDA-MB-231 and SK-BR-3 cells with OIP5-AS1 downregulation and found a significant increase of miR-129-5p in sh-OIP5-AS1 cells compared with control cells in both lines (P < .01) ( Figure 3F ). Together, these findings suggest that miR-129-5p can bind to OIP5-AS1 and the downregulation of OIP5-AS1
can increase the expression of miR-129-5p in breast cancer cells.
| Upregulation of miR-129-5p inhibits breast cancer cell growth, proliferation and migration, and induces cell apoptosis in vitro
We next examined the function of miR-129-5p in breast cancer cells by expressing miR-129-5p in SK-BR-3 and MDA-MB-231 cells ( Figure 4A ). CCK-8 assays showed reduced proliferation in both miR-129-5p-expressing cell lines compared with the negative control (Coi) group (P < .01) ( Figure 4B ). In miR-129-5p-expressing cells, colony formation ability was significantly reduced compared with controls (P < .01; Figure 4C ). Wound healing and Transwell assays showed that migration and invasion, respectively, were significantly inhibited in the miR-129-5p group compared with controls (P < .01; Figure 4D ,E). We also detected a higher apoptosis rate in miR-129-5p-expressing cells compared with controls (P < .01; Figure 4F ). Consistent with these results, Bax and cleaved caspase 3 were increased and Bcl-2 was reduced in cells with miR-129-5p upregulation ( Figure 4G ).
| Opa interacting protein 5-antisense RNA 1 functions as a ceRNA of SOX2
Our previous studies focused on the role of SOX2 in breast cancer and found that the 3′-UTR region of SOX2 has a miR-129-5p binding site using starBase. 24 Thus, we next explored whether SOX2 is involved in the OIP5-AS1/miR-129-5p axis. We first constructed luciferase reporters containing the wild-type SOX2 3′-UTR or 3′-UTR mutated for the miR-129-5p binding sequence ( Figure 5A ). In MDA-MB-231 cells, miR-129-5p decreased luciferase activity of the wt-SOX2 3′-UTR vector but not the mut-SOX2 3′-UTR vector (P < .01; Figure 5B ).
We next explored the relationship among OIP5-AS1, miR-129-5p and SOX2. Downregulation of OIP5-AS1 as well as upregulation of miR-129-5p ( Figure 5D ) resulted in decreased SOX2 levels. We have shown that miR-129-5p binds OIP5-AS1 and the expression of miR-129-5p is regulated by OIP5-AS1. These results suggest that OIP5-AS1 functions as a ceRNA by acting as a sponge for miR-129-5, releasing SOX2 from the inhibitory effect of miR-129-5p. 
| Downregulation
| Downregulation of OIP5-AS1 increases miRNA-129-5p and decreases SOX2 levels, suppresses breast cancer cells and induces cell apoptosis in vivo
We established subcutaneous xenografts in nude mice to evaluate the role of OIP5-AS1 in breast cancer in vivo. OIP5-AS1 downregulation significantly inhibited tumor growth (P < .01; Figure 7A ,B)
as well as tumor weight (P < .01) ( Figure 7C ). qRT-PCR assay confirmed dramatically reduced OIP5-AS1 in the sh-OIP5-AS1 tumors (P < .01; Figure 7D ) as well as increased miR-129-5p and decreased SOX2 expressions ( Figure 7E ). Western blotting also showed decreased SOX2 protein in sh-OIP5-AS1 tumors ( Figure 7F ).
Immunohistochemistry showed lower Ki-67 and SOX2 expression in sh-OIP5-AS1 tumors ( Figure 7G ), and OIP5-AS1 downregulation caused a remarkable induction of apoptosis in vivo ( Figure 7H ).
Together, these results show that OIP5-AS1 downregulation suppressed breast cancer cell growth and proliferation and induced cell apoptosis in vivo.
| D ISCUSS I ON
In the present study, we investigated the role of lncRNA OIP5-AS1 in promoting breast cancer. OIP5-AS1 was increased in breast cancer regulate ZEB1 through miR-448. 26 The lncRNA small ubiquitin-like modifier 1 pseudogene 3 (SUMO1P3) is highly expressed in breast cancer tissue samples and is associated with higher staging and worse prognosis. 27 The long intergenic non-coding RNA regulator of reprogramming (ROR) is a ceRNA of miR-145 and regulates the expression of ARF6 in triple-negative breast cancer, thus regulating invasion. 28 In the present study, we found that OIP5-AS1 was significantly increased in breast cancer tissue samples and cells. We further found reduced proliferation, invasion and migration as well as increased apoptosis of breast cancer cells as a result of downregulation of OIP5-AS1. However, according to our results, there was no significant correlation between the expression of OIP5-AS1 and estrogen receptor (ER) status (P = .053), progesterone receptor (PR) status (P = .472), human epidermal growth factor receptor 2 (Her-2) status (P = 0.624) and Ki-67 status (P = .147) ( Table 3) .
As breast cancer was divided into four subtypes according to the status of ER, PR, Her-2 and Ki-67, the role of OIP5-AS1 in breast cancer may be independent of subtype. However, experiments with more samples in multiple centers are needed.
The functional role of a lncRNA depends on the downstream molecules that it regulates, including the miRNAs it affects in its function as a ceRNA. The lncRNA mesenchymal stem cells-upregulated factor (MUF) functions as a ceRNA of miR-34a to regulate Snail1 activity and modulate hepatocellular carcinoma (HCC) progression. 29 The lncRNA HOXD-AS1 is upregulated in HCC tissues and competitively binds miR-130a-3p, regulating EZH2 and MMP2 expression and facilitating HCC metastasis. 30 By online software prediction, we found the possibility of the existence of the OIP5-AS1/miR-129-5p/ SOX2 axis.
miR-129-5p was reported as a suppressor in many types of tumors. Low expression of miR-129-5p in breast cancer was associated with poor prognosis. 31 miR-129-5p acts as a suppressor of autophagy in breast cancer cells and decreases their radioresistance by targeting high-mobility group protein 1 (HMGB1). 32 In the present study, we found that OIP5-AS1 functions as ceRNA of SOX2 through miR-129-5p to promote the progression of breast cancer. Our luciferase assays showed that miR-129-5p binds and represses OIP5-AS1 and we also showed that miR-129-5p could bind and repress SOX2. Thus, the expression of SOX2 could also be influenced by the downregulation of OIP5-AS1 or by the upregulation of miR-129-5p. Our findings suggest that downregulation of OIP5-AS1 can inhibit the progression of breast cancer by targeting SOX2 through miR-129-5p upregulation ( Figure 8 ).
As the SOX2 transcription factor regulates many downstream processes, further exploration is needed to clarify the cellular functions of the OIP5-AS1/miR-129-5p/SOX2 axis.
The progression of breast cancer involves multiple steps and is a complex process involving multiple factors. The phenotype of breast cancer is regulated by a complex network. To explore whether there are other factors regulated by OIP5-AS1, we used starBase v2.0 (http://starbase.sysu.edu.cn) to predict OIP5-AS1-targeted miRNAs and mRNAs in pan-cancer. A total of 229 miRNAs were predicted F I G U R E 8 Under normal conditions, the binding of micro RNA (miR)-129-5p to sex-determining region Y-box 2 (SOX2) mRNA leads to the degradation of SOX2 mRNA, thus maintaining normal levels of SOX2. In the case of Opa interacting protein 5-antisense RNA 1 (OIP5-AS1) overexpression, OIP5-AS1 competitively binds with miR-129-5p as a miRNA sponge and releases SOX2 mRNA from the inhibitory effect of miR-129-5p. The increased SOX2 can thus promote the malignant phenotype of breast cancer as OIP5-AS1-targeted miRNA in pan-cancer, whereas 120 were significant in breast cancer. Other significant miRNAs besides miR-129-5p and their target sites and alignment sequence are listed in Table S1 . Furthermore, 1659 ceRNA networks were predicted as OIP5-AS1-related in pan-cancer, among which the expression of FAM13B, ERRFL1, ELK4, RCOR1, SLC4A7 showed important roles in the OIP5-AS1 related network. More research is needed to clarify the OIP5-AS1-regulated network in breast cancer.
This study has some limitations. The follow-up time of our selected clinical patients was short and not sufficient to draw correlations between OIP5-AS1 expression and miR-129-5p expression with the survival and prognosis of breast cancer patients.
Together, our findings highlight the important role of the lncRNA OIP5-AS1 in promoting the progression of breast cancer by targeting SOX2 through miR-129-5p. To the best of our knowledge, this is the first study to characterize the role of the lncRNA OIP5-AS1 in breast cancer. These results provide new targets for the diagnosis and treatment of breast cancer and call for more studies on the detailed mechanisms underlying the function of lncRNAs.
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